Merck & Co., Inc.

“Accenture, Nike and Merck are among the first of nearly 50 customers signing on to use our new model.”

Merck is among the first customers adopting Workday's new Flex Credits consumption pricing model.

“as it relates to Merck, there was a strategic partnership we announced”

Veeva clarifies its Merck relationship is a strategic partnership rather than a commitment to use Veeva everywhere, a read-through on Merck's selective R&D-software standardization.

“ABP-two zero six and ABP-two thirty four biosimilar candidates to Opdivo and Keytruda respectively have completed enrollment in each of their comparative clinical studies”

Amgen is developing a biosimilar to Merck's Keytruda, signaling future biosimilar competition against Merck's flagship oncology franchise.

“how you're thinking about potential impact from the launch of Merck's oral PCSK9 and how you're adapting your commercial strategy there?”

An analyst raises Merck's forthcoming oral PCSK9 inhibitor as a competitive threat to Amgen's Repatha franchise; read-through that Merck is entering the PCSK9 market.

“ProHeart contributions, if any, coming from Merck's product Interceptor Plus Quantum, the last part of that, I would say, no. We do not see any meaningful contributions here.”

Zoetis says rival Merck Animal Health's Interceptor Plus Quantum is not meaningfully denting ProHeart, implying Merck's new parasiticide launch has gained limited traction against Zoetis.

“For INT, our individualized cancer therapy, developed in partnership with Merck, we recently reported positive five-year phase 2 data in adjuvant melanoma”

Moderna's INT individualized cancer therapy is a 50/50 partnership with Merck; positive five-year melanoma data supports the joint oncology program.

“I wanted to see if these are maybe similar in scope to how Veeva has come to work with the likes of Merck and BI, and what was discussed under kind of those large strategic engagements.”

An analyst cites Merck alongside Boehringer Ingelheim as an example of Veeva's large, strategic, cross-product-line customer engagements with top pharma companies.

“As you said, we are trying our combination versus KEYTRUDA.”

Regeneron's fianlimab/Libtayo melanoma trial is powered against Merck's KEYTRUDA as the comparator arm.

“your first round in the PD-1 battle, the development and commercial kind of competition with Merck”

Merck (Keytruda) was BMS's main rival in the first PD-1 era; BMS reflects on those competitive learnings as it enters the PD-1/VEGF bispecific race.

“Sotatercept, I think, came in around 33 or 35, so we edged that out, and it's a different kind of medicine, obviously, and it's not an apples-to-apples comparison”

Insmed benchmarks TPIP's 35.5% PVR reduction in PAH against Merck's sotatercept (~33-35%), positioning TPIP favorably on efficacy.

“our next wave of biosimilar candidates is advancing in Phase III clinical development, featuring biosimilars to OPDIVO, KEYTRUDA and OCREVUS.”

Amgen has a KEYTRUDA biosimilar in Phase III, signaling future biosimilar competition for Merck's largest product as its patents approach expiry.

“No word yet in terms of exactly when the Merck approval will be in the U.S. as they have said, they expected approval late this year, early next year.”

Zoetis notes an upcoming Merck dermatology product approval expected in the U.S. late 2025/early 2026, a read-through on Merck Animal Health entering the derm category where Zoetis leads.

“why your Trope-two development strategy seems to be relatively conservative versus what AstraZeneca and Daiichi are exploring, especially if you have a differentiated asset.”

An analyst contrasts Merck's TROP-2 ADC development pace with the more aggressive programs of AstraZeneca (and Daiichi Sankyo).

“This is the first two-drug regimen without an HIV integration strand transfer inhibitor to demonstrate non-inferior efficacy and safety versus the broadly used three-drug insti-based regimen Biktarvy.”

Merck positions its two-drug HIV regimen as non-inferior to Gilead's flagship Biktarvy, a competitive read-through on Gilead's leading HIV franchise.